Pacira BioSciences, Inc.: financial statements

PCRXNASDAQHealthcare · Pharmaceutical Preparations

Price

$36.48

November 16, 2026Market cap $1.5B

What Ploutos Investor adds for Pacira BioSciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+3.7% a year over 2 years

Line202320242025Average a year
Revenue $675M$701M$726M+3.7%
Cost of revenue $185M$170M$150M-9.9%
Gross profit $490M$531M$577M+8.4%
Operating income $88M-$73M$19M-53.2%
Net income $42M-$100M$7.0M-59.0%
Earnings per share $0.89-$2.15$0.16-57.6%
Earnings per share, basic $0.91-$2.15$0.16-58.0%
Margins
Gross margin 72.6%75.7%79.4%
Operating margin 13.0%-10.5%2.6%
Net margin 6.2%-14.2%1.0%

Financial statements

PCRX's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: EXPAREL $538M, ZILRETTA $111M, Iovera $20M, Bupivacaine Liposome Injectable Suspension $3.3M, Royalty $2.7M
  • 2024: EXPAREL $549M, ZILRETTA $118M, Iovera $23M, Bupivacaine Liposome Injectable Suspension $7.3M, Royalty $3.8M
  • 2025: EXPAREL $575M, ZILRETTA $117M, Iovera $24M, Bupivacaine Liposome Injectable Suspension $6.9M, Royalty $3.6M
Product202320242025Share 2025
EXPAREL$538M$549M$575M79%
ZILRETTA$111M$118M$117M16%
Iovera$20M$23M$24M3.3%
Bupivacaine Liposome Injectable Suspension$3.3M$7.3M$6.9M1.0%
Royalty$2.7M$3.8M$3.6M0.5%

By segment

PCRX's revenue by product line from 2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$46M Leases58.3% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$46M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Goodwill by segment

Dec 31, 2025

Total goodwill

$20M

The company does not state its goodwill by segment, at December 31, 2025. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

58.3%

+37.3 pts

The company paid 58.3% in tax on its profit, 37.3 points above the US federal rate (21.0%). Below, the reasons it gives.

The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were -1.6% on the same quarter a year earlier, and receivables +6.6%. Inventory was -17.9%, against +8.6% for the cost of sales.

a year earlier 58 days
63 days
a year earlier 419 days
317 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Taxes: deferred and paid

The deferred part was 65.8% of the tax charge in the year to Dec 31, 2025. The rows show the last 3 years.

Cash taxes paid were 268.0% of the current tax charge in the year to Dec 31, 2025.

Deferred share, year to Dec 31, 2025$6.5M of $9.8M
65.8%
Deferred share, year to Dec 31, 2024$21M of $36M
56.6%
Deferred share, year to Dec 31, 2023$16M of $20M
79.1%
$9.0M paid, $3.4M current
268.0%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Pacira BioSciences's filings show?

These are Pacira BioSciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PCRX's financials

Didn't find what you were looking for?

Ask us
How much revenue did PCRX have in 2025?

Pacira BioSciences had revenue of $726M and net income of $7.0M in fiscal 2025, a net margin of 1.0%.

How much debt does PCRX have?

On December 31, 2025 Pacira BioSciences had total assets of $1.3B, debt of $372M and shareholders' equity of $693M.

How much free cash flow does PCRX have?

In fiscal 2025 Pacira BioSciences had cash from operations of $152M and spent $15M on capital expenditure, leaving $137M of free cash flow.

Where are the figures from?

From Pacira BioSciences, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.